Skip to content
  • Debatforum
  • Seneste
  • Populære
  • Bruger
Temaer
  • Light
  • Dark

Kollaps
FORSIDEN
Log ind Opret konto

Genmab — Juli 2020

Planlagt Fastgjort Låst Flyttet Genmab
1.1k Indlæg 1 Posters 0 Visninger
  • Ældste til nyeste
  • Nyeste til ældste
  • Most Votes
Svar
  • Svar som emne
Login for at svare
Denne tråd er blevet slettet. Kun brugere med emne behandlings privilegier kan se den.
  • Helge_LarsenPI-redaktørH Offline
    Helge_LarsenPI-redaktørH Offline
    Helge_LarsenPI-redaktør
    wrote on sidst redigeret af
    #969

    Tak bibob.

    1 Reply Last reply
    0
    • B Offline
      B Offline
      bibob
      wrote on sidst redigeret af
      #970

      Tak Sukker. Selvfølgelig. 😉

      1 Reply Last reply
      0
      • E Offline
        E Offline
        E_L
        wrote on sidst redigeret af
        #971

        Phase 3 Amivantamab trial,
        1000 participants!!

        1 Reply Last reply
        0
        • E Offline
          E Offline
          E_L
          wrote on sidst redigeret af
          #972

          A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer (MARIPOSA) https://www.clinicaltrials.gov/ct2/show/NCT04487080?recrs=ab&cond=Lung+Cancer&sfpd_s=07%2F14%2F2020&sfpd_d=14&sel_rss=new14

          1 Reply Last reply
          0
          • M Offline
            M Offline
            Mcjean
            wrote on sidst redigeret af
            #973

            Wouw thats a lot, isnt it?

            1 Reply Last reply
            0
            • SolsenS Offline
              SolsenS Offline
              Solsen
              wrote on sidst redigeret af
              #974

              Yes it is. They perhaps need power to show better effect. What do Osimertinib have in revenue ?

              1 Reply Last reply
              0
              • SolsenS Offline
                SolsenS Offline
                Solsen
                wrote on sidst redigeret af
                #975

                Tagrisso: $982M (+56%) Q120

                1 Reply Last reply
                0
                • E Offline
                  E Offline
                  E_L
                  wrote on sidst redigeret af
                  #976

                  Novartis also with a new trial , for patients that want to switch to Ofa from another CD20 https://www.clinicaltrials.gov/ct2/show/NCT04486716?term=NCT04486716&draw=2&rank=1

                  1 Reply Last reply
                  0
                  • SolsenS Offline
                    SolsenS Offline
                    Solsen
                    wrote on sidst redigeret af
                    #977

                    Lidt mere om Lazertinib https://www.fiercebiotech.com/biotech/janssen-taps-south-korea-s-yuhan-for-tagrisso-rival Gode data og baren er sat højt.

                    1 Reply Last reply
                    0
                    • SolsenS Offline
                      SolsenS Offline
                      Solsen
                      wrote on sidst redigeret af
                      #978

                      Barren skulle der stå 😉

                      1 Reply Last reply
                      0
                      • J Offline
                        J Offline
                        Joakim_Von_And
                        wrote on sidst redigeret af
                        #979

                        De stoffer I nævner Amivantamab, Lazertinib..Hvem har de forbindelse til ? Kan ikke finde ud af om det er godt eller skidt for genmab.

                        1 Reply Last reply
                        0
                        • G Offline
                          G Offline
                          gentogen
                          wrote on sidst redigeret af
                          #980

                          Amivantamab (JNJ-61186372) is a bispecific antibody that targets EGFR and cMet, two validated cancer targets. The two antibodies used to create amivantamab (JNJ-61186372) were both created by Genmab.

                          1 Reply Last reply
                          0
                          • Helge_LarsenPI-redaktørH Offline
                            Helge_LarsenPI-redaktørH Offline
                            Helge_LarsenPI-redaktør
                            wrote on sidst redigeret af
                            #981

                            God morgen. 🙂

                            1 Reply Last reply
                            0
                            • B Offline
                              B Offline
                              bibob
                              wrote on sidst redigeret af
                              #982

                              God morgen. 🙂

                              1 Reply Last reply
                              0
                              • S Offline
                                S Offline
                                Sukkeralf
                                wrote on sidst redigeret af
                                #983

                                Der må falde en milestone når fase III med amivantamab starter op - ligeledes når første registreringsansøgning indsendes sidt på året. Bliver spændende at se hvor backloaded disse aftaler er

                                1 Reply Last reply
                                0
                                • S Offline
                                  S Offline
                                  Sukkeralf
                                  wrote on sidst redigeret af
                                  #984

                                  Nogen der husker strukturen på en lignende aftale. Den er selvfølgelig backloaded i høj grad, men må også være ret simpel, da man jo for mange af programmerne ikke kendte targets og dermed mulige indikationer. Så mon den alene går på første indikation der kommer hele vejen, for de milestones det gælder klinisk udvikling og registrering. Gætter på at mindst halvdelen af milestonepakken er salgsmilestones

                                  1 Reply Last reply
                                  0
                                  • B Offline
                                    B Offline
                                    BioShare
                                    wrote on sidst redigeret af
                                    #985

                                    Gik alt, alt for langsomt med at få indrullet patienterne i det ACCORD-studie....trist. I stedet startes et nye forsøg op "overseas"...

                                    1 Reply Last reply
                                    0
                                    • B Offline
                                      B Offline
                                      BioShare
                                      wrote on sidst redigeret af
                                      #986

                                      Sorry, forkert chat 😞

                                      1 Reply Last reply
                                      0
                                      • E Offline
                                        E Offline
                                        E_L
                                        wrote on sidst redigeret af
                                        #987

                                        from 2019 : Janssen DuoBody Collaboration
                                        In July 2012, we entered into a collaboration with Janssen to create and develop bispecific antibodies using our DuoBody platform. Under this agreement, Janssen received an exclusive worldwide license to use the DuoBody technology to create panels of bispecific antibodies (up to 10 DuoBody programs) to multiple disease target combinations. We recorded an upfront payment of $3.5 million from Janssen and will potentially be entitled to milestone and

                                        1 Reply Last reply
                                        0
                                        • E Offline
                                          E Offline
                                          E_L
                                          wrote on sidst redigeret af
                                          #988

                                          and license payments of up to approximately $175.0 million, as well as royalties for each commercialized DuoBody product. Janssen may terminate this agreement in whole or with respect to any particular target binding pair upon providing 120 days' prior written notice to us in accordance with the terms of the agreement.

                                          1 Reply Last reply
                                          0

                                          Hello! It looks like you're interested in this conversation, but you don't have an account yet.

                                          Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.

                                          With your input, this post could be even better 💗

                                          Tilmeld Log ind

                                          • Log ind

                                          • Har du ikke en konto? Tilmeld

                                          • Login or register to search.
                                          • First post
                                            Last post
                                          0
                                          • Debatforum
                                          • Seneste
                                          • Populære
                                          • Bruger